The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients

We investigated amino acid heterogeneity in the variable regions of the E2/NS1 viral protein in interferon‐responsive and interferon‐nonresponsive patients with chronic hepatitis C virus infection. The study assessed whether any particular heterogeneity pattern(s) could be useful in predicting responsiveness to interferon treatment. The nucleic acid sequences of the hepatitis C virus genome were analyzed from six patients with chronic hepatitis treated with an interferon‐β, three of whom did not respond to the therapy and another three who showed remarkable improvement in the serum levels of liver enzymes and hepatitis C virus RNA after 6 mo. The complementary DNA clones propagated from each of the nonresponders showed significant diversity of both nucleotide and amino acid sequence, especially at the hypervariable region 1 within the putative E2/NS1 gene of the virus, suggesting that these patients were infected with a large heterogeneous pool of hepatitis C virus variants. In contrast, the responders showed little or no diversity in the sequence of the complementary DNA clones, suggesting that they were infected with one or a small population of viral genotypes containing significantly less variability in the E2/NS1 hypervariable region 1. These results suggested that a large variable population of hepatitis C virus genotypes is implicated in patients who are nonresponders to interferon treatment. In addition, a significant change in the hepatitis C virus genotype population was observed in nonresponders after interferon treatment. This may reflect a differential viral sensitivity to interferon, selective immune pressure by the host or both. (HEPATOLOGY 1992;16:619–624.)

[1]  H. Okamoto,et al.  Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. , 1992, The Journal of general virology.

[2]  M A Nowak,et al.  Antigenic diversity thresholds and the development of AIDS. , 1991, Science.

[3]  H. Okamoto,et al.  Nucleotide sequence of the genomic RNA of hepatitis C virus isolated from a human carrier: comparison with reported isolates for conserved and divergent regions. , 1991, The Journal of general virology.

[4]  O. Yokosuka,et al.  Resolution of acute hepatitis C after therapy with natural beta interferon , 1991, The Lancet.

[5]  J. McDonald,et al.  Can the response to interferon treatment be predicted in patients with chronic active hepatitis C? , 1991, Australian and New Zealand journal of medicine.

[6]  R. Purcell,et al.  Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[7]  N. Kato,et al.  Hypervariable regions in the putative glycoprotein of hepatitis C virus. , 1991, Biochemical and biophysical research communications.

[8]  Matthew J. Brauer,et al.  Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. , 1991, Virology.

[9]  Eugene R. Schiff,et al.  Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa , 1989 .

[10]  S. Banks,et al.  Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. , 1989, The New England journal of medicine.

[11]  K. Mullis,et al.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. , 1988, Science.

[12]  F. Sanger,et al.  DNA sequencing with chain-terminating inhibitors. , 1977, Proceedings of the National Academy of Sciences of the United States of America.